[ad_1]
Illustrating the University of Colorado Cancer Center’s analysis power within the space of blood cancersthe American Most cancers Society Journal lately requested CU Most cancers Middle members Andrew KentPhD, and And PollyeaMD, MS, to present readers an replace on the most recent advances in leukemia remedy.
In the article published in the journal’s April 2023 editionKent and Pollyea discuss two new leukemia medicine that had been lately accredited by the FDA and the way they mirror new developments in leukemia analysis.
The primary spotlighted drug, asciminib, stops most cancers from spreading by inhibiting the BCR-ABL gene, whereas the second drug, brexucabtagene autoleucel, is a CAR T cell immune remedy that harnesses the affected person’s personal immune system to assault and destroy most cancers cells.
We spoke with Kent — who was a resident and a fellow within the CU School of Medicine earlier than changing into an teacher of hematology and CU Most cancers Middle member earlier this summer season — concerning the paper and the medicine on which it focuses.
[ad_2]
Source link
Discussion about this post